Shilpak Chatterjee , Ph.D.

Senior Scientist
Cancer Biology & Inflammatory Disorder
details-banner

Research Focus

Immunometabolism, Tumor immunology, T cell Biology

Research Interest

Immunotherapy of cancer is emerging as a powerful weapon in the oncological armamentarium. Considerable efforts are being made to harness the cytotoxic potential of the T cells to eradicate cancer. Yet, elimination of established tumor is impeded due to the dysfunctionality of the anti-tumor T cells at the tumor site. The major objective of our lab is to understand the mechanism (s) dampening the objective repose of the anti-tumor T cells. Primarily we are focusing on:

  • Elucidating the role of cellular metabolism in remodelling the anti-tumor response of T cells.
  • Determine the crosstalk between metabolic adaptation and stress response pathways in augmenting the therapeutic efficacy of anti-tumor T cell.
  • Determine the role of metabolic requirements in shaping up the functionality of tumor associated myeloid cells.

Credentials

  • Postdoctoral Research (2011-2018), Medical University of South Carolina, Charleston, USA
  • PhD (2006-2011)Chittaranjan National Cancer Institute, Kolkata, India

Patents & Publications

PATENTS 

  1. US patent: Process to Generate Superior Anti-Tumor Memory Cells. Provisional application filed 05/15/2015 for MUSC-FRD Technology ID: P1569. PCT filed 04/28/2017. Shikhar Mehrotra, Mike Nishimura, Pravin Kesarwani and Shilpak Chatterjee.
  2. US patent: CD38-mediated Metabolic Axis in Anti-Tumor Immunotherapy. Provsional application filed 11/09/2016 for MUSC-FRD Technology ID: P1716. PCT filed 11/09/2017. Shikhar Mehrotra and Shilpak Chatterjee.

 

PUBLICATIONS

  1. Chatterjee S*, Chakraborty P*, Daenthanasanmak A, Iamsawat S, Andrejeva G, Luevano LA, Wolf M, Baliga U, Krieg C, Beeson CC, Mehrotra M, Hill EG, Rathmell JC, Yu XZ, Kraft AS, Mehrotra S.;Targeting PIM Kinase with PD1 inhibition Improves Immunotherapeutic Anti-Tumor T Cell Response,2018,Clinical Cancer Research (Accepted) ,,, PMID, doi
  2. Wilson KR, Kang IH, Baliga U, Xiong Y, Chatterjee S, Moore E, Parthiban B, Thyagarajan K, Borke JL, Mehrotra S, Kirkwood KL, LaRue AC, Ogawa M, Mehrotra M. ; Hematopoietic Stem Cells as a Novel Source of Dental Tissue Cells , 2018 , Science Report , 8(1) , 8026 , PMID 29795229 , doi 10.1038/s41598-018-26258-y.
  3. Daenthanasanmak A, Wu Y, Iamsawat S, Nguyen HD, Bastian D, Zhang M, Sofi MH, Chatterjee S, Hill EG, Mehrotra S, Kraft AS, Yu XZ. ; PIM-2 protein kinase negatively regulates T cell responses in transplantation and tumor immunity , 2018 , Journal of Clinical Investigation , 128(7) , 2787-2801 , PMID 29781812 , doi 10.1172/JCI95407
  4. Chatterjee S, Daenthanasanmak A, Chakraborty P, Wyatt MW, Dhar P, Selvam SP, Fu J, Zhang J, Nguyen H, Kang I, Toth K, Al-Homrani M, Husain M, Beeson G, Ball L, Helke K, Husain S, Garrett-Mayer E, Hardiman G, Mehrotra M, Nishimura MI, Beeson CC, Bupp MG, Wu J, Ogretmen B, Paulos CM, Rathmell J, Yu XZ, Mehrotra S. ; CD38-NAD+Axis Regulates Immunotherapeutic Anti-Tumor T Cell Response , 2018 , Cell Metabolism , 27(1) , 85-100 , PMID 29129787 , doi 10.1016/j.cmet.2017.10.006
  5. Klarquist J, Tobin K, Farhangi Oskuei P, Henning SW, Fernandez MF, Dellacecca ER, Navarro FC, Eby JM, Chatterjee S, Mehrotra S, Clark JI, Le Poole IC. ; Ccl22 Diverts T Regulatory Cells and Controls the Growth of Melanoma , 2016 , Cancer Research , 76(21) , 6230-6240 , PMID 27634754 , doi 10.1158/0008-5472.CAN-16-0618
  6. Kesarwani P, Chakraborty P, Gudi R, Chatterjee S, Scurti G, Toth K, Simms P, Husain M, Armeson K, Husain S, Garrett-Mayer E, Vasu C, Nishimura MI, Mehrotra S. ; Blocking TCR restimulation induced necroptosis in adoptively transferred T cells improves tumor control. , 2016 , Oncotarget , 7(43) , 69371-69383 , PMID 27750220 , doi 10.18632/oncotarget.12674.
  7. Banerjee A*, Thyagarajan K*, Chatterjee S*, Chakraborty P, Kesarwani P, Soloshchenko M, Al-Hommrani M, Andrijauskaite K, Moxley K, Janakiraman H, Scheffel MJ, Helke K, Armenson K, Palanisamy V, Rubinstein MP, Garrett Mayer E, Cole DJ, Paulos CM, Voelkel-Johnson C, Nishimura MI, Mehrotra S. ; Lack of p53 Augments Anti-Tumor Functions in Cytolytic T Cells , 2016 , Cancer Research , 76(18) , 5229-40 , PMID 27466285 , doi 10.1158/0008-5472.CAN-15-1798
  8. Nguyen HD, Chatterjee S, Haarberg KM, Wu Y, Bastian D, Heinrichs J, Fu J, Daenthanasanmak A, Schutt S, Shrestha S, Liu C, Wang H, Chi H, Mehrotra S, Yu XZ. ; Metabolic reprogramming of alloantigen-activated T cells after hematopoietic cell transplantation , 2016 , Journal of Clinical Investigation , 126(4) , 1337-52 , PMID 26950421 , doi 10.1172/JCI82587
  9. Kesarwani P, Thyagarajan K, Chatterjee S, Palanisamy V, Mehrotra S. ; Anti-oxidant capacity and anti-tumor T cell function: A direct correlation. , 2015 , Oncoimmunology , 4(1) , e985942 , PMID 25949871 , doi 10.4161/2162402X.2014.985942
  10. Eby JM, Kang HK, Tully ST, Bindeman WE, Peiffer DS, Chatterjee S, Mehrotra S, Le Poole IC. ; CCL22 to Activate Treg Migration and Suppress Depigmentation in Vitiligo , 2015 , Journal of Investigative Dermatology , 135(6) , 1574-1580 , PMID 25634358 , doi 10.1038/jid.2015.26
  11. Song JH, An N, Chatterjee S, Kistner-Griffin E, Mahajan S, Mehrotra S and Kraft AS. ; Deletion of Pim kinases elevates the cellular levels of reactive oxygen species and sensitizes to K-Ras-induced cell killing , 2015 , Oncogene , 34(28) , 3728-36 , PMID 25241892 , doi 10.1038/onc.2014.306
  12. Chatterjee S, Thyagarajan K, Kesarwani P, Song JH, Soloshchenko M, Fu J, Bailey S, Kraft AS, Vasu C, Paulos CM, Yu XZ, Mehrotra S. ; Reduced CD73 Expression by IL-1β Programmed Th17 Cells Improves Tumor Control. , 2014 , Cancer Research , 74(21) , 6048-59 , PMID 25205101 , doi 10.1158/0008-5472.CAN-14-1450
  13. Eby JM, Kang HK, Klarquist J, Chatterjee S, Mosenson JA, Nishimura MI, Garrett-Mayer E, Jack Longley B, Engelhard VH, Mehrotra S, Le Poole IC. ; Immune Responses In A Mouse Model Of Vitiligo With Spontaneous Epidermal De- And Repigmentation. , 2014 , Pigment Cell Melanoma Res , 27(6) , 1075-85 , PMID 24935676 , doi 10.1111/pcmr.12284
  14. Husain S, Abdul Y, Webster C, Chatterjee S, Kesarwani P, Mehrotra S. ; Interferon-gamma (IFN-γ)-mediated retinal ganglion cell death in human tyrosinase T cell receptor transgenic mouse , 2014 , PLoS ONE , 9(2) , e89392 , PMID 24586745 , doi 10.1371/journal.pone.0089392
  15. Chatterjee S, Eby J, Al-Khami AA, Soloshchenko M, Kang H, Kaur N, Naga O, Murali A, Nishimura MI, Le Poole IC, Mehrotra S ; A Quantitative Increase in Regulatory T Cell Controls Development of Vitiligo. , 2014 , Journal of Investigative Dermatology , 134(5) , 1285-94 , PMID 24366614 , doi 10.1038/jid.2013.540
  16. Chatterjee S, Chakraborty P, Banerjee K, Sinha A, Adhikary A, Das T, Choudhuri SK. ; Selective induction of apoptosis in various cancer cells irrespective of drug sensitivity through a copper chelate, copper N-(2 hydroxy acetophenone) glycinate: crucial involvement of glutathione , 2013 , Biometal , 26 (3) , 517-34 , PMID 23733180 , doi 10.1007/s10534-013-9637-z.
  17. Chatterjee S, Das S, Chakraborty P, Manna A, Chatterjee M, Choudhuri SK. ; Myeloid derived suppressor cells (MDSCs) can induce the generation of Th17 response from naïve CD4+ T cells. , 2013 , Immunobiology , 218 (5) , 718-24 , PMID 22995935 , doi 10.1016/j.imbio.2012.08.271.
  18. Chakraborty P*, Chatterjee S*, Ganguly A, Saha P, Adhikary A, Das T, Chatterjee M, Choudhuri SK ; Reprogramming of TAM toward proimmunogenic type through regulation of MAP kinases using a redox-active copper chelate , 2012 , J Leukoc Biol , 91 (4) , 609-619 , PMID 22279179 , doi 10.1189/jlb.0611287
  19. Ganguly A, Chakraborty P, Banerjee K, Chatterjee S, Basu S, Sarkar A, Chatterjee M, Choudhuri SK ; Iron N-(2-hydroxy acetophenone) glycinate (FeNG), a non-toxic glutathione depletor circumvents doxorubicin resistance in Ehrlich ascites carcinoma cells in vivo. , 2012 , Biometal , 25 (1) , 149-63 , PMID 21915630 , doi 10.1007/s10534-011-9493-7
  20. Ganguly A, Basu S, Chakraborty P, Chatterjee S, Sarkar A, Chatterjee M, Choudhuri SK. ; Targeting Mitochondrial Cell Death Pathway to Overcome Drug Resistance with a Newly Developed Iron Chelate , 2010 , PLoS One , 5(6) , e11253 , PMID 20582168 , doi 10.1371/journal.pone.0011253.
  21. Chatterjee S*, Mookerjee A*, Mookerjee-Basu J*, Chakraborty P, Ganguly A, Adhikary A, Mukhopadhyay D, Ganguli S, Banerjee R, Ashraf M, Biswas J, Das PK, Sa G, Chatterjee M, Das T, Choudhuri SK. ; A novel copper chelate modulates tumor associated macrophages to promote anti-tumor response of T cells , 2009 , PLoS One , 4(9) , e7048 , PMID 19756150 , doi 10.1371/journal.pone.0007048.
  22. Mookerjee A, Basu JM, Majumder S, Chatterjee S, Panda GS, Dutta P, Pal S, Mukherjee P, Efferth T, Roy S, Choudhuri SK. ; A novel copper complex induces ROS generation in doxorubicin resistant Ehrlich ascitis carcinoma cells and increases activity of antioxidant enzymes in vital organs in vivo , 2006 , BMC Cancer , 6 , 267 , PMID 17107616 , doi 10.1186/1471-2407-6-267